Skip to main content
Loading

Poster Presentation: Lead Identification & Optimization topic: De Novo Protein Sequencing for Identification of Neutralizing Antibodies in Human Plasma

22 Sep 2025
Target Selection & Mechanisms of Action
The antibody response to vaccination and infection is key to immune defense and human antibody therapeutic development, offering a blueprint for targeted treatments. While B-cell sequencing aids human antibody discovery, it may miss the full diversity of circulating antibodies, as only 2-3% of B cells are in circulation, and not all produce antibodies. We demonstrate a mass spectrometry proteomics-based approach to sequencing neutralizing antibodies from serum of a patient vaccinated against SARS-CoV-2. Following de novo sequencing, we recombinantly expressed 12 antibodies. Six recombinant antibodies exhibited similar or higher binding affinities than the original natural polyclonal antibody and exhibited neutralizing capabilities.
Industry Expert
Olga Kapustina, Scientific Sales Executive - Rapid Novor

Rapid Novoor